4-AP


Also found in: Encyclopedia.

4-AP

4-aminopyridine.
References in periodicals archive ?
While the toxic, epileptogenic side effects resulting from 4-AP likely arise from the indiscriminate blockade of various CNS [K.
This finding was followed by the first studies in myelin basic protein (MBP)-reactive rat T cells [35-36,78-80] and the first demonstration that 4-AP and other nonspecific [K.
3 channel, with better selectivity/potency profiles and experimental therapeutic effects [18-19] than 4-AP [35-36,78,80].
3 channel than 4-AP or 3,4-DAP, they are, at present, handicapped as viable therapeutics because of their short half-life of approximately 20 min [19]; synthetic toxin analogues are being developed to overcome such limitations [106].
While further studies are needed before this drug can go to the Food and Drug Administration for approval, the current study concluded that 4-AP is safe.
Over the next six months, continued uptake of Ampyra will come from increased use among progressive MS patients, conversion of current non-users into users, and switching of patients currently treated with compounded 4-AP.
FAMPYRA is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine).
FAMPYRA is a modified-release (prolonged-release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine).